Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $260.00.
BIO has been the subject of a number of research analyst reports. TheStreet lowered shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a report on Monday, September 18th.
Shares of Bio-Rad Laboratories (BIO) opened at $253.22 on Wednesday. The stock has a market cap of $8,830.00, a PE ratio of 81.96, a PEG ratio of 3.90 and a beta of 0.88. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15. Bio-Rad Laboratories has a twelve month low of $169.19 and a twelve month high of $268.40.
A number of institutional investors and hedge funds have recently made changes to their positions in BIO. Canada Pension Plan Investment Board bought a new stake in Bio-Rad Laboratories during the 2nd quarter valued at about $113,000. Pacad Investment Ltd. bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at about $113,000. First Manhattan Co. raised its holdings in shares of Bio-Rad Laboratories by 71.6% in the 3rd quarter. First Manhattan Co. now owns 599 shares of the medical research company’s stock valued at $133,000 after purchasing an additional 250 shares in the last quarter. Turner Investments LLC bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter valued at about $136,000. Finally, Meeder Asset Management Inc. raised its holdings in shares of Bio-Rad Laboratories by 3,333.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 618 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 600 shares in the last quarter. Institutional investors own 64.27% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) Receives Average Recommendation of “Buy” from Analysts” was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/11/15/bio-rad-laboratories-inc-bio-receives-average-recommendation-of-buy-from-analysts.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.